You are here

P&T News

December 24

Treatment contains stronger liraglutide dose than Victoza
Experts suggest less-stringent DBP target for people with diabetes
Findings may offer way to keep current therapies effective
Launch expected in second quarter of 2015

December 23

Experts find benefit in screening all adults without known hypertension
Treatment indicated for patients who have progressed on Yervoy

December 22

Several new drugs win agency nod
New use seen for bisphosphonates
Researcher hopes to improve on ZMapp vaccine
Treatment achieves significant reduction in HDV levels over 4 weeks

December 19

Researchers find tobacco-specific nitrosamines
Risk reduced by 97% in subjects 50 years of age and older
But MARIANNE trial finds Kadcyla treatment options non-inferior
Drug targets women with defective BRCA genes found by new test

December 18

CD3 T-cell engager joins ranks of world’s most expensive cancer treatments
NIH study examines prescribing patterns
Rate of functional independence nearly twice as high with clot removal versus usual care alone
Newest fluoroquinolone to win agency’s okay

December 17

First pathogen-reduction system for plasma approved in U.S.
Defendants responsible for ‘unprecedented national tragedy,’ U.S. Attorney says
Largest hospitals will get stronger as smaller ones get weaker, analysts predict

December 16

Comedian Joan Rivers’ death spurs increased scrutiny
Study data show test predicts risk better in black women
Authors say ERs will need to provide wider range of health-care services
Smoking remains leading cause of preventable death and disease in U.S.

December 15

Peptide activates innate repair receptor, turns off inflammation
Combo treatment increases progression-free survival versus vemurafinib alone
Vaccine candidate stimulates production of neutralizing antibodies
Reform reduces incidence of preventable, hospital-acquired health problems

December 12

Capecitabine/ibandronate combo no better than ibandronate alone
Finding could lead to new testing and treatment methods
No significant improvement in progression-free survival
Phase III data reported at neuropsychopharmacology meeting

December 11

Expert warns of return to ‘dark ages’ of medicine
Bortezomib/fulvestrant shows promise in mid-stage trial
Researchers see no effect on walking pain of lumbar spinal stenosis



From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.